Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Highly Accessed Editorial

NK4 therapy: a new approach to target angiogenesis and inflammation in rheumatoid arthritis

Bradley J Rabquer12 and Alisa E Koch2*

Author Affiliations

1 Department of Biology, 611 E Porter St, Albion College, Albion, MI 49224, USA

2 Department of Internal Medicine, 109 Zina Pitcher Pl., University of Michigan Medical School, Ann Arbor, MI 48109, USA

For all author emails, please log on.

Arthritis Research & Therapy 2013, 15:119  doi:10.1186/ar4320


See related research by Tsunemi et al.: http://arthritis-research.com/content/15/4/R75

Published: 30 September 2013

Abstract

Rheumatoid arthritis (RA) is a progressive autoimmune disease characterized by synovial membrane hyperplasia, inflammation, and angiogenesis. Hepatocyte growth factor (HGF) and its receptor, c-Met, are both overexpressed in the RA synovium. NK4 is an antagonist of HGF which has been shown to inhibit tumor growth, metastasis, and angiogenesis. In an experimental model of RA, NK4 gene therapy inhibited joint damage and inflammation in both preventative and therapeutic models. NK4 treatment therefore represents a possible therapeutic option in combating RA.